This is not a walk-in benefit
The Medicare GLP-1 Bridge runs 1 July 2026 through 31 December 2027. When a prior authorization is approved, the patient pays $50 per month for Wegovy (injection or pill), Foundayo, or Zepbound KwikPen. Nothing else on a pharmacy shelf is in the demonstration.
You cannot self-submit. A licensed clinician files against the chart. VitalHound assembles a checklist so that filing is complete. It does not determine eligibility and it does not enroll anyone in a plan.
Write the indication that matches the path
Bridge is the obesity-and-overweight demonstration. If the prescription is for type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH, CMS expects a standard Part D claim — not Bridge. Filing the wrong path wastes a cycle and can park a $50 copay where TrOOP credit should have accrued.
The checklist should state the indication in the same words the label and the chart use. Informal phrases such as 'weight loss shot' are how PAs bounce.
BMI, date, and device belong on the same page
Published Bridge tiers are BMI ≥35; BMI ≥30 with listed heart or kidney conditions; or BMI ≥27 with listed cardio-metabolic history. The height, weight, and BMI date should come from the visit that supports the PA, not from a hallway estimate.
If the product is Zepbound, the PA must specify KwikPen. Other Zepbound presentations are outside the demonstration. Confirm the NDC with the pharmacy before anyone hits submit.
Who is already closed
A person who already filled a GLP-1 through Part D in 2026 is generally ineligible for Bridge. So is someone who lacks Part D or an MA-PD. Extra Help does not open a closed path and does not discount the $50.
Tell the patient, in writing, that the $50 will not appear as Part D spending and will not count toward the deductible or TrOOP.
What the clinician actually transmits
The filing goes through the Bridge processor, not as an ordinary Part D claim with a hopeful copay. Attach tried-and-failed lifestyle notes if the form asks, list contraindication review, and name the product-device pair.
If Bridge is denied, manufacturer cash remains a legal path. A commercial savings card is not legal on Medicare.
Questions
Can the patient fax the PA themselves?
Does a Bridge approval mean Part D now covers obesity drugs?
What if the chart says type 2 diabetes and obesity?
Is VitalHound the processor?
Not sure this applies to you?
Answer a few questions and see your own numbers.
Free to see which path is likely cheapest for your coverage.
Check my options